Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapies CREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each dose Findings highlight CREXONT as a key...Read more
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this type of bladder cancer have limited choices beyond radical cystectomy,...Read more
AMX0114 was generally well-tolerated, with no treatment-related serious adverse events Amylyx will proceed with opening enrollment of second cohort Data are being presented at the 36th International Symposium on ALS/MND CAMBRIDGE, Mass. / Dec 05, 2025 / Business Wire / Amylyx...Read more
U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2 Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency on December 8, 2025 Scheduled Type C Meeting with United States Food & Drug...Read more
In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of any CD19-directed CAR T cell...Read more
WASHINGTON, Dec. 4, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limited the protocol to a maximum of 90 doses of tradipitant. The...Read more
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Praxis Precision Medicines | 58.02 30.54 | $247.99 |
| Krystal Biotech | 12.17 5.48 | $234.13 |
| Nutex Health | 7.37 4.70 | $164.16 |
| Intuitive | 6.71 1.18 | $575.34 |
| Bright Minds Biosciences | 6.47 8.93 | $78.89 |
| Penumbra | 5.94 2.02 | $300.66 |
| Movano Health | 5.61 180.39 | $8.72 |
| United Therapeutics | 5.21 1.08 | $489.31 |
| ResMed | 5.04 2.00 | $256.55 |
| Bolt Biotherapeutics | 4.86 869.59 | $5.42 |
| Humana | 4.83 1.91 | $257.85 |
| Galecto | 4.57 19.97 | $27.46 |
| CooperCompanies | 4.37 5.67 | $81.40 |
| Abivax | 3.88 3.51 | $114.52 |
| Medpace | 3.35 0.61 | $548.12 |
| GE HealthCare | 2.94 3.56 | $85.46 |
| Alumis | 2.86 34.46 | $11.16 |
| Jazz Pharmaceuticals | 2.79 1.67 | $169.70 |
| Company | Volume | Last Trade |
|---|---|---|
| Incannex Healthcare | 89,335,901 | $0.46 |
| PharmaCyte Biotech | 75,080,597 | $1.20 |
| MaxCyte | 61,630,597 | $1.47 |
| Kala Bio | 47,191,522 | $0.90 |
| Pfizer | 46,011,062 | $26.01 |
| Intensity Therapeutics | 33,779,554 | $0.51 |
| Clearmind Medicine | 26,060,885 | $0.13 |
| Recursion | 23,680,015 | $4.71 |
| Plus Therapeutics | 22,983,615 | $0.65 |
| Biomea Fusion | 22,304,083 | $1.22 |
| Microbot Medical | 22,226,526 | $2.37 |
| Applied Therapeutics | 18,331,940 | $0.22 |
| Sana Biotechnology | 17,095,832 | $5.13 |
| Geron | 16,873,106 | $1.31 |
| PacBio | 16,566,511 | $2.39 |
| Sangamo Therapeutics | 16,138,790 | $0.49 |
| Moderna | 16,010,572 | $27.58 |
| Capricor Therapeutics | 15,617,941 | $26.62 |
| Bristol-Myers Squibb | 15,293,020 | $52.15 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
